148 related articles for article (PubMed ID: 498009)
1. High dose cytosine arabinoside (HDARAC) in refractory acute leukemia.
Rudnick SA; Cadman EC; Capizzi RL; Skeel RT; Bertino JR; McIntosh S
Cancer; 1979 Oct; 44(4):1189-93. PubMed ID: 498009
[TBL] [Abstract][Full Text] [Related]
2. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia.
Kantarjian HM; Estey EH; Plunkett W; Keating MJ; Walters RS; Iacoboni S; McCredie KB; Freireich EJ
Am J Med; 1986 Sep; 81(3):387-94. PubMed ID: 3463209
[TBL] [Abstract][Full Text] [Related]
3. Central nervous system toxicity of high-dose cytosine arabinoside.
Grossman L; Baker MA; Sutton DM; Deck JH
Med Pediatr Oncol; 1983; 11(4):246-50. PubMed ID: 6888324
[TBL] [Abstract][Full Text] [Related]
4. [Value of high-dose cytosine-arabinoside in the treatment of resistant acute leukemia].
Witz F; Olive D; Lederlin P; Bordigoni P; Troussard X; Grosbois B; Schaison G; Cornu G
Presse Med; 1987 Feb; 16(4):159-62. PubMed ID: 2950446
[TBL] [Abstract][Full Text] [Related]
5. Mitoxantrone in the treatment of relapsed and refractory acute leukemia.
Moore JO; Olsen GA
Semin Oncol; 1984 Sep; 11(3 Suppl 1):41-6. PubMed ID: 6385265
[TBL] [Abstract][Full Text] [Related]
6. High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia.
Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Mertelsmann R; Planker M; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
Semin Oncol; 1987 Jun; 14(2 Suppl 1):73-7. PubMed ID: 3473685
[TBL] [Abstract][Full Text] [Related]
7. Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase.
Capizzi RL; Poole M; Cooper MR; Richards F; Stuart JJ; Jackson DV; White DR; Spurr CL; Hopkins JO; Muss HB
Blood; 1984 Mar; 63(3):694-700. PubMed ID: 6696996
[TBL] [Abstract][Full Text] [Related]
8. Clinical results and pharmacokinetics of high-dose cytosine arabinoside (HD ARA-C).
Breithaupt H; Pralle H; Eckhardt T; von Hattingberg M; Schick J; Löffler H
Cancer; 1982 Oct; 50(7):1248-57. PubMed ID: 7104969
[TBL] [Abstract][Full Text] [Related]
9. Systemic high-dose ara-C for the treatment of meningeal leukemia in adult acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
Morra E; Lazzarino M; Inverardi D; Brusamolino E; Orlandi E; Canevari A; Pagnucco G; Bernasconi C
J Clin Oncol; 1986 Aug; 4(8):1207-11. PubMed ID: 3461134
[TBL] [Abstract][Full Text] [Related]
10. Continuous infusion high-dose cytosine arabinoside in refractory childhood leukemia.
Ochs J; Sinkule JA; Danks MK; Look AT; Bowman WP; Rivera G
J Clin Oncol; 1984 Oct; 2(10):1092-7. PubMed ID: 6593435
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia.
Cannistra SA; DiCarlo J; Groshek P; Kanakura Y; Berg D; Mayer RJ; Griffin JD
Leukemia; 1991 Mar; 5(3):230-8. PubMed ID: 1826536
[TBL] [Abstract][Full Text] [Related]
12. [High-dose cytarabine treatment in acute leukemias and leukemic meningiosis: clinical aspects and pharmacokinetics].
Nowrousian MR; Seeber S; Miller AA; Anders C; Ohl S; Schmidt CG
Onkologie; 1985 Feb; 8(1):26-32. PubMed ID: 3885117
[TBL] [Abstract][Full Text] [Related]
13. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
Kornblau SM; Gandhi V; Andreeff HM; Beran M; Kantarjian HM; Koller CA; O'Brien S; Plunkett W; Estey E
Leukemia; 1996 Oct; 10(10):1563-9. PubMed ID: 8847890
[TBL] [Abstract][Full Text] [Related]
14. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
Early AP; Preisler HD; Slocum H; Rustum YM
Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutic effects of a combination of intermediate-dose cytosine arabinoside, adriamycin and vincristine in relapsed acute leukemia].
Takahashi I; Yorimitsu S; Inagaki T; Sekito N; Hayashi N; Nishimura M; Aoyama S; Nakada H; Ohmoto E; Uchida K
Gan To Kagaku Ryoho; 1987 Feb; 14(2):485-9. PubMed ID: 3813576
[TBL] [Abstract][Full Text] [Related]
16. Toxicity of high dose Ara-C in children and adolescents.
Barrios NJ; Tebbi CK; Freeman AI; Brecher ML
Cancer; 1987 Jul; 60(2):165-9. PubMed ID: 3594353
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of a continuous infusion of high-dose ara-C in conjunction with a fixed dose of 2'-deoxycytidine (IND 28108) in patients with refractory leukemia: an interim report.
Grant S; Baker M; Bhalla K
Leukemia; 1993 Dec; 7(12):1933-8. PubMed ID: 8255091
[TBL] [Abstract][Full Text] [Related]
18. [Intermediate- and high-dose cytosine arabinoside therapy in acute refractory leukemia].
Ohshima A; Yoshida K; Sato T; Miyazaki S; Yanagisawa M; Nakayama Y; Takahashi T; Mamiya S; Fukusima Y; Miura AB
Gan To Kagaku Ryoho; 1987 Jan; 14(1):192-5. PubMed ID: 3800405
[TBL] [Abstract][Full Text] [Related]
19. High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis.
Iacoboni SJ; Plunkett W; Kantarjian HM; Estey E; Keating MJ; McCredie KB; Freireich EJ
J Clin Oncol; 1986 Jul; 4(7):1079-88. PubMed ID: 3459811
[TBL] [Abstract][Full Text] [Related]
20. Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study.
Kreis W; Budman DR; Chan K; Allen SL; Schulman P; Lichtman S; Weiselberg L; Schuster M; Freeman J; Akerman S
Leukemia; 1991 Nov; 5(11):991-8. PubMed ID: 1961042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
